Wilson Sonsini Advises Doron Therapeutics on $11 Million Series A
Wilson Sonsini Advises Doron Therapeutics on $11 Million Series A
Client Highlights12/02/24
Life Sciences
Our Industry Coverage
With one of the largest life sciences practices in the U.S., Wilson Sonsini’s industry legacy dates to the formative years of biotech and medical device. Working closely with scientists and entrepreneurs who grew their companies into thriving businesses, we have worked alongside to support their endeavors from whiteboard to clinical trial and beyond.
Industry Highlights
Celebrating our founders’ successes
2020
Seer IPO Raises $175 Million in Nasdaq Debut
Decision / Risk Analysis2020
Artelo Biosciences Announces $6.6 Million Public Offering
Cannabinoid-Based Therapies2020
PMV Pharmaceuticals Joins Nasdaq with $211 Million IPO
Drug Discovery2020
Athira Pharma Closes $204 Million IPO
Drug Discovery2020
HintMD is Acquired by Revance Therapeutics
Mobile Healthcare Platform2020
ALX Oncology Prices IPO at $161 Million
Immuno-Oncology2020
Applied Molecular Transport Closes IPO at $154 Million
Pharmaceuticals2020
Oric Pharmaceuticals IPO Raises $120 Million
Drug Discovery2020
Lumos Pharma Sets Sights on SPAC
Drug Discovery2013
NanoString Files IPO Worth $54 Million
Molecular DiagnosticsAttorneys
focused
on this
industry
recent news
we want to share
with you
Wilson Sonsini Advises GI Windows Surgical on $37 Million Series B
Wilson Sonsini Advises GI Windows Surgical on $37 Million Series B
Client Highlights11/25/24
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
Client Highlights11/19/24
Firm Advises Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on Constructive Bio’s $58 Million Series A